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ABSTRACT
Femoropopliteal (FP) artery-in stent restenosis (ISR) is a daunting management problem 
that we continue to face. FP artery-ISR rates after primary stent implantation are relatively 
high. Although repeat FP artery-ISR and the need for additional interventions remain all 
too common, little consensus exists regarding the best treatment algorithm. In this article, 
we review the limitations of the currently used devices for the endovascular treatment of FP 
artery-ISR and discuss which strategies are the most effective and safe.
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INTRODUCTION
Atherosclerotic disease in the femoropopliteal (FP) artery consists of perfusion to the legs 
and feet. Percutaneous transluminal angioplasty (PTA) has been routinely used to manage 
FP artery disease and is recommended as an alternative to surgical bypass. Recently, newer 
endovascular approaches such as covered stent, drug-eluting balloon (DEB), drug-eluting 
stent (DES), or catheter based atherectomy have been introduced as treatment options for 
FP artery disease. Nevertheless, FP artery-in stent restenosis (ISR) is still a major challenge 
with endovascular therapy. Limited data exist on the risk factors for FP artery-ISR that 
require target lesion revascularization (TLR) or target vessel revascularization (TVR) after 
endovascular revascularization in FP artery disease.1)2) The goal of this article is to help the 
practicing cardiovascular interventionist consider the optimal choices for the management of 
patients with FP artery-ISR.
PATHOPHYSIOLOGY OF FP ARTERY-ISR
FP artery is the most common arterial segment treated by endovascular therapy.3) 
Endovascular therapy for FP artery disease, at least in Korea, has been largely limited to 
conventional balloon angioplasty (BA) or (nitinol) self-expandable stent implantation, and 
these are considered safe and relatively effective therapies.3) After BA or self-expandable stent 
implantation, the local vasculature reacts with an inflammatory response that precipitates 
neointimal hyperplasia (NIH).4) In addition to lesion-specific factors, such as a longer lesion 
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length and smaller vessel diameter, patient characteristics, including diabetes mellitus 
and smoking history, can increase the risk of ISR.5)6) Although the use of self-expandable 
stents has improved the patency rate of PTA in FP artery disease, the incidence of FP artery-
ISR ranges from 15% to 32%, and a FP artery-ISR peak seems to occur between 9 and 15 
months after PTA. After 2 years, the occurrence of FP artery-ISR is low, and probably, the 
lesions are more related to the evolution of atheromatous disease rather than NIH.7)8) Stent 
implantations are associated with mechanical stressors including vessel elongation, torsion, 
flexion, and extension increasing the risk of the development of FP artery-ISR. In particular, 
the distal one-third of the FP artery has poorer endovascular patency rates.9)
WHICH IS CURRENTLY THE BEST STRATEGY FOR THE 
TREATMENT OF FP ARTERY-ISR?
A number of endovascular treatments and tools are available in the interventionists' 
armamentarium for treating FP artery-ISR, such as repeat BA or stent implantation (with 
a self-expandable stent, covered stent, or DES), cutting or scoring balloon angioplasties 
angioplasty, cryoplasty, and catheter based atherectomy, all providing good immediate 
success rates (Table 1). Nevertheless, no standard treatment exists for the treatment of FP 
artery-ISR.
DEB
They is standard BA Catheter surface coated with a thin layer of anti-proliferative drug 
combined with an excipient or spacer substance, which facilitates drug transfer to the 
vessel wall.10) Randomized trials have shown that DEB for FP artery disease is associated 
with less restenosis and TLR than conventional BA.11) In the treatment of FP artery-ISR, the 
advantages of DEB include drug delivery and inhibition of NIH, more uniform drug-tissue 
transfer and potential amelioration of vessel healing due to the absence of a pro-inflammatory 
durable polymer surface coating. Recently, several randomized trials comparing DEB with 
conventional BA for the treatment of FP artery-ISR have been reported. Most previously 
assessed data on FP artery-ISR treatment with DEB have been convincing (Figure 1). The 
Femoral Artery In-Stent Restenosis (FAIR) trial showed that DEB for FP artery-ISR was 
associated with less recurrent restenosis and a better clinical outcome than conventional BA 
without an apparent difference in safety issue.12) Freedom from TLR was significantly higher in 
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Table 1. Endovascular treatment or FP artery-ISR
BA
Conventional BA
Cutting BA
DEB angioplasty
Stent in stent
(Nitinol) self-expandable stent implantation
DES implantation
Catheter based atherectomy
Laser atherectomy
Directional atherectomy
Rotational atherectomy
Bypass surgery
BA = balloon angioplasty; DEB = drug-eluting balloon; DES = drug-eluting stent; FP = femoropopliteal; ISR = in 
stent restenosis.
the DEB group than in the conventional BA group (90.8% vs. 52.6% at 12 months; p<0.001). 
In the Paclitaxel Balloon Versus Standard Balloon in In-Stent Restenoses of the Superficial 
Femoral Artery (PACUBA) trial, the 12-month primary patency rates were 40.7% (95% 
confidence interval [CI], 0.26–0.64) versus 13.4% (95% CI, 0.05–0.36) (log-rank p=0.02) in 
the DEB versus conventional BA group.13) Data from a single center showed a one year primary 
patency rate of 92.1%, regarding the role of DEB in the treatment of FP artery-ISR.14) In a 2-year 
follow-up, a primary patency rate of 70.3% was observed.15) In the Drug-Eluting Balloon in 
peripherAl inTErvention for In-Stent Restenosis (DEBATE-ISR) trial, the use of DEB for the 
treatment of FP artery-ISR showed a significant reduction in restenosis recurrence compared 
with conventional BA.16) At 1 year, the TLR rates were 13% in the DEB group and 31% in the 
conventional BA group (p=0.045). However, the use of DEB for treatment of FP artery-ISR had 
similar results as conventional BA in terms of the TLR after 3 years of follow-up suggesting a 
late catch-up phenomenon between 1 and 3 years of follow-up.17) Recently, the IN.PACT Global 
study showed that the rate of clinically driven TLR at 1 year was 7.3%, with the use of DEB for 
the treatment of patients with FP artery-ISR.18) The use of DEB as the primary treatment of FP 
artery-ISR has the following advantages. First, DEB provides local delivery of a target-specific 
drug with theoretical application to the entire arterial surface. Second, its use avoids the 
downside of a catheter based atherectomy, such as potential embolization or vessel rupture. 
Third, prolonged DEB inflation enhances the short-term patency outcome in the literature. 
Fourth, DEBs leave nothing behind and lower metallic stent utilization. Nevertheless, 
recurrent ISR following the use of DCB is a problem that needs to be considered.
DES
Three different types of stents are available in real clinical practice, a (nitinol) self-expandable 
stent, covered stent (stent graft), and DES. The use of a covered stent is an additional tool 
to treat FP artery-ISR. Some retrospective studies have shown favorable results with covered 
stents.19)20) However, the efficacy of a covered stent in the treatment of FP artery-ISR has not 
been fully demonstrated yet. Data evaluating the use DEB for FP artery-ISR are relatively 
sparse. Few studies have investigated the role of DES for the treatment of FP artery-ISR. 
In Zilver PTX (Cook Medical, Bloomington, IN, USA), the treatment of 119 FP artery-ISR 
lesions with a paclitaxel-eluting stent had an estimated primary patency rate of 95.7% at 6 
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Figure 1. Freedom from TLR at one year in patients with FP artery-ISR. 
DEBATE-ISR = Drug-Eluting Balloon in peripherAl inTErvention for In-Stent Restenosis; FAIR = Femoral Artery In-
Stent Restenosis; FP = femoropopliteal; ISR = in stent restenosis; TLR = target lesion revascularization.
months and 78.8% at 1 year.21) A retrospective study compared conventional BA with DES 
implantation for FP artery-ISR. At 2 years, the Kaplan-Meier estimated freedom from the 
recurrent ISR rates were 79.3% in the DES group and 20.2% in the conventional BA group, 
respectively (p<0.001).22) One study compared DES implantation with conventional BA in 
the treatment of FP artery-ISR. DES implantation was associated with significantly lower 
incidences of recurrent restenosis (44.1% vs. 90.3%; p<0.001).23) Many operators advocate a 
strategy of avoiding repeat stent implantation among patients with FP artery-ISR. When flow-
limiting dissection occurs in a subset of patients undergoing conventional BA, then repeat 
stent implantation may be necessary to maintain an adequate luminal flow. In this condition, 
DES implantation is strongly recommended over self-expandable stent implantation.
MECHANICAL DEBULKING WITH A CATHETER BASED 
ATHERECTOMY DEVICE
Unlike balloons and stents, which push plaque into the vessel wall, atherectomy offers the 
ability to debulk the plaque burden within the vessel.24) Laser atherectomy uses high energy, 
a monochromatic light beam, to alter or dissolve the atheromatous plaque without damaging 
the surrounding tissue. The EXCImer Laser Randomized Controlled Study for Treatment 
of FemoropopliTEal In-Stent Restenosis (EXCITE ISR) study showed the superiority of 
the combination of laser atherectomy and conventional BA versus conventional BA alone 
for treating FP artery-ISR.25) In the SALVAGE study, the strategy of laser atherectomy and 
conventional BA for the treatment of FP artery-ISR was safe and associated with high 
procedural success.26) However, the use of laser atherectomy is not widely available in Korea.
Directional atherectomy is considered a minimally invasive treatment that removes 
atheromatous plaques and restores blood flow in the native FP artery. Two types of 
directional atherectomy devices are available, the SilverHawk™ system (Medgadget, Eugene, 
OR, USA) and TurboHawk™ system (Medtronic, Minneapolis, MN, USA). They are forward 
cutting directional atherectomy devices with a rotating blade inside a tubular housing with 
a collection area (nosecone). In directional atherectomy, however, the theoretical advantage 
of minimizing repetitive barotrauma to the vessel wall and inhibition of NIH have not 
been achieved as clinical benefits in the treatment of FP artery-ISR. On the other hand, the 
JetStream™ atherectomy device (Boston Scientific, Marlborough, MA, USA) is a rotational 
atherectomy system. This device uniquely combines rotablation with an aspiration capability. 
The use of JetStream atherectomy showed favorable acute results in treating FP artery-ISR 
with high procedure success, no device-stent interaction, and favorably low TLR rates. The 
incidence of primary patency was 72% at 6 months.27)
COMBINED TREATMENTS WITH CATHETER BASED 
ATHERECTOMY AND CONVENTIONAL BA
The combination of catheter based atherectomy with the subsequent use of DEB has the 
advantage of combined debulking and neointimal modification from atherectomy plus 
the enhanced anti-restenotic effect of DEB angioplasty. The efficacies of this strategy are 
published by some authors.28)29) The patency rate at 1 year were between 66.7% and 84.7%. 
This is much better than the use of atherectomy devices alone as a single treatment strategy 
for FP artery-ISR (Figure 2).
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CONCLUSION
The endovascular treatment of FP artery-ISR has increased over the years and will keep on 
increasing in the future. Many endovascular devices have been developed and are currently in 
use. There are still mixed findings on the outcomes after endovascular treatment of FP artery-
ISR. Although repeat FP artery-ISR and the need for additional interventions remain all too 
common, little consensus exists regarding the best treatment algorithm. The use of DEB could 
be recommended as the first choice of devices to treat FP artery-ISR because of its efficacy and 
ease of use. In complex lesions, such as in-stent total occlusion and critical limb ischemia with 
diabetes, DES implantation might be another option. Directional atherectomy for FP artery-ISR 
seems to be limited by a low patency rate. However, some data suggest that the use of rotational 
atherectomy is safe and effective. Another field of improvement is the use of drug-eluting 
devices in association to rotational atherectomy which need to be further evaluated.
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